Digestive Diseases and Sciences

, Volume 50, Issue 6, pp 1148–1155

Pegylated Interferon α -2a With or Without Ribavirin in HCV/HIV Coinfection: Partially Blinded, Randomized Multicenter Trial

  • Mandana Khalili
  • David Bernstein
  • Ellen Lentz
  • Christine Barylski
  • Margaret Hoffman-Terry


We evaluated the safety and efficacy of peginterferon α-2a (pegIFNα-2a), with or without ribavirin, in 154 HCV/HIV coinfected patients. All received pegIFNα-2a (180 μg/week) for 12 weeks, with those achieving an early virologic response (EVR) continued on monotherapy through week 48. Patients without an EVR were randomized at week 14 to also receive ribavirin (800 mg/day) or placebo through week 48. Patients with detectable HCV RNA at week 24 were discontinued. An EVR occurred in 59 of 154 patients on monotherapy, and a sustained virologic response (SVR) occurred in 19 of 55 of those achieving an EVR and continuing monotherapy through week 48. One week 12 nonresponder receiving pegIFNα-2a plus ribavirin, and none receiving pegIFNα -2a plus placebo, achieved a SVR. Discontinuations for adverse events occurred in 10 of 154 patients before, and 16 of 131 after, week 14. HIV RNA and CD4 counts did not change significantly during treatment. PegIFNα -2a was therefore at least as effective as standard interferon and ribavirin combination therapy and was well tolerated, without a negative impact on HIV parameters.

Key Words

pegIFNα-2a hepatitis C coinfection efficacy therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853–860, 1998Google Scholar
  2. 2.
    Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kuman PN, Mintz L, Wallach FR, Nemo GJ: Viral Activation Transfusion Study Investigators: Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 135:17–26, 2001PubMedGoogle Scholar
  3. 3.
    Khalili M, Behm BW: Hepatitis C in the setting of HIV co-infection. Microbes Infect 4:1247–1251, 2002CrossRefPubMedGoogle Scholar
  4. 4.
    Rosenthal E, Poirée M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, Myers RP, Morlat P, Pialoux G, Pol S, Cacoub P: GERMIVIC Joint Study Group: Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 17:1803–1809, 2003CrossRefPubMedGoogle Scholar
  5. 5.
    Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, Yoffe B: Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 33:240–247, 2001CrossRefPubMedGoogle Scholar
  6. 6.
    Sherman KE, Rouster SD, Chung RT, Rajicic N: Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 34:831–837, 2002CrossRefPubMedGoogle Scholar
  7. 7.
    Bräu N, Bini EJ, Shahidi A, Aytaman A, Xiao P, Stancic S, Eng R, Brown ST, Paronetto F: Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol 97:2071–2078, 2002PubMedGoogle Scholar
  8. 8.
    Klein MB, Lalonde RG, Suissa S: The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 33:365–372, 2003PubMedGoogle Scholar
  9. 9.
    Sherman KE, O’Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, Wilber J: Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 31:2679–2682, 1993PubMedGoogle Scholar
  10. 10.
    Bonacini M, Govindarajan S, Blatt LM, Schmid P, Conrad A, Lindsay KL: Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 6:203–208, 1999PubMedGoogle Scholar
  11. 11.
    Soto B, Sánchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, Rey C, Abad MA, Rodríguez M, Sales Gilabert M, Gonzalez F, Miron P, Caruz A, Relimpio F, Torronteras R, Leal M, Lissen E: Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 26:1–5, 1997Google Scholar
  12. 12.
    Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30:1054–1058, 1999Google Scholar
  13. 13.
    Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283:74–80, 2000PubMedGoogle Scholar
  14. 14.
    Melvin DC, Lee JK, Belsey E, Arnold J, Murphy RL: The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS 14:463–465, 2000PubMedGoogle Scholar
  15. 15.
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965, 2001PubMedGoogle Scholar
  16. 16.
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982, 2002CrossRefPubMedGoogle Scholar
  17. 17.
    Pérez-Olmeda M, Núñez M, Romero M, Gonzalez J, Castro A, Arribas JR, Pedreira J, Barreiro P, Garcia-Samaniego J, Martin-Carbonero L, Jiménez-Nacher I, Soriano V: Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 17:1023–1028, 2003PubMedGoogle Scholar
  18. 18.
    Nasti G, Di Gennaro G, Tavio M, Cadorin L, Tedeschi RM, Talamini R, Carbone A, Tirelli U: Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and ribavirin. AIDS 15:1783–1787, 2001PubMedGoogle Scholar
  19. 19.
    Sulkowski M, Felizarta F, Slim J, Dieterich D, Goodman R, Ball L: Final results of daily vs 3-times weekly interferon alpha-2b plus ribavirin for the treatment of hepatitis C infection in HIV-infected persons: a multi-center, randomized open-label study. Presented at 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10–14, 2003, abstract 841Google Scholar
  20. 20.
    Rockstroh JK, Mudar M, Lichterfeld M, Nischalke HD, Klausen G, Golz J, Dupke S, Notheis G, Stein L, Mauss S; German Clinical AIDS Working group (KAAD): Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. AIDS 16:2083–2085, 2002PubMedGoogle Scholar
  21. 21.
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeux J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group: Peginterferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Eng J Med 351:438–450, 2004Google Scholar
  22. 22.
    Ferenci P: Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 53:15–18, 2004PubMedGoogle Scholar
  23. 23.
    Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, Pockros PJ, Haussinger D, Smith CI, Lin A, Pappas SC: Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 37:500–506, 2002PubMedGoogle Scholar
  24. 24.
    Lafeuillade A, Hittinger G, Chadapaud S: Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 357:280–281, 2001PubMedGoogle Scholar
  25. 25.
    Guyader D, Poinsignon Y, Cano Y, Saout L: Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C. J Hepatol 37:289–291, 2002Google Scholar
  26. 26.
    Butt AA: Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Read 13:344–348, 2003PubMedGoogle Scholar
  27. 27.
    Vogt MW, Hartshorn KL, Furman PA, Chou TC, Fyfe JA, Coleman LA, Crumpacker C, Schooley RT, Hirsch MS: Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 235:1376–1379, 1987PubMedGoogle Scholar
  28. 28.
    Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D: Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 36:97–100, 2003PubMedGoogle Scholar
  29. 29.
    Taylor LE, Costello T, Alt E, Yates G, Tashima K: Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus co-infected individuals. AIDS 16:1700–1701, 2002PubMedGoogle Scholar
  30. 30.
    Gries JM, Torriani FJ, Rodriguez-Torres M, Soriano V, Borucki MJ, Piliero P, Lissen E, Sukowski M, Wang K, Dieterich D, Back D: Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HCV/HIV coinfection: final results of a randomized clinical study. Presented at 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8–11, 2004, abstract 136LBGoogle Scholar
  31. 31.
    Perronne C, Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel F, Morand P, Salmon D, Pialoux G, Raguin G, Grillot-Courvalin C, Cacoub P; ANRS HC02-RIBAVIC study group: Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated-interferon-alfa-2b plus ribavirn vs interferon-alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients. Presented at 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8–11, 2004, abstract 117LBGoogle Scholar
  32. 32.
    Chung R, Andersen J, Volberding P, Robbins G, Liu T, Sherman K, Peters M, Koziel M, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C; AIDS Clinical Trials GroupA5071 Study Team:Arandomized, controlled trial of PEG-interferon alfa-2a plus ribavirin vs interferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV co-infected persons: follow-up results of ACTG A5071. Presented at 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8–11, 2004, abstract 110Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Mandana Khalili
    • 1
    • 5
  • David Bernstein
    • 2
  • Ellen Lentz
    • 3
  • Christine Barylski
    • 3
  • Margaret Hoffman-Terry
    • 4
  1. 1.University of California, San FranciscoSan Francisco
  2. 2.Division of HepatologyNorth Shore University HospitalManhasset
  3. 3.Roche Laboratories Inc.Nutley
  4. 4.Lehigh Valley HospitalAllentownUSA
  5. 5.San Francisco General HospitalSan FranciscoUSA

Personalised recommendations